Short communication · 30 Jul 2022
Short communicationPublished 15 Sep 2020
About Agile Sciences Inc
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Agile Sciences, Inc. is a pre-clinical stage biopharmaceutical company based in Raleigh, North Carolina that is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections. The antibiotics market generated global sales of $39.6 billion in 2013. Despite this very large market, there are many infections that are not treatable by marketed antibiotics due to the growing issues of antibiotic resistance. These infections are responsible for an estimated 20,000 deaths in the United States each year with an associated $20 billion in direct health care costs and $35 billion in lost productivity. Antibiotic resistance is one the greatest health care challenges for the future, according to the World Health Organization. Despite this, very few new classes of antibiotics have been introduced over the past two decades due mainly to the early onset of resistance. Agile Sciences core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial resistance mechanisms through a novel mode of action, effectively rendering bacteria unable to protect themselves. These 2-AI compounds have been shown to: • Restore the activity of antibiotics against multi-drug resistant (MDR) Gram-positive and Gram-negative bacterial pathogens. • Reduce the dose of current antibiotics required to achieve bacterial clearance, sometimes by as much as 200-fold. • Mitigate the acquisition of antibiotic resistance • Inhibit and disperse bacterial communities, known as biofilms Agile Sciences’ 2-AI compounds have the potential to revitalize the antibiotic market by restoring drug resistant bacterial strains to many existing classes of antibiotics to address this large unmet medical need. The company’s primary focus is on treatment of Gram-negative MDR bacterial infections; along with treatment of lung infections in cystic fibrosis (CF) patients; and treatment of chronic wound infections.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 3 Sep 2018
Cell science 2017: Bone marrow mesenchymal stem cells differentially affect the aggressiveness of cancer cell subtypes_ Tamara Lah Turnsek_ Proffesor, Inc,USA
Research article · 27 Feb 2020
The Link between Organizational Agility and Leadership: A Research in Science Parks
Research article · 19 Dec 2022
An Open Label, Balanced, Randomized, Two Treatments, Two Sequences, Four Periods, Fully Replicate, Crossover, Bioequivalence Study of Abiraterone Acetate 250 mg Tablets of Abbott Laboratories De Colombia Versus ZYTIGA® (Abiraterone Acetate) 250 mg Tablets of Janssen Biotech, Inc. Under Fasting Condition in Healthy Subjects
Conference abstract · 2020
Pharma-2012 : Rapid fatty acid and microbial identification using the MIDI sherlock® microbial identification system - Michael Alexander - MIDI Inc.
More from this journal
The newest in Journal of Pharmaceutical Microbiology.
Research article · 17 Oct 2023
Molecular Identification of Extended Spectrum Beta Lactamase Producing Organisms from Students in a University Community
Conference abstract · 27 Aug 2022
Fear among Syrians: a Proposed Cutoff Score for the Arabic Fear of the COVID 19 Scale
Conference abstract · 27 Aug 2022
ENTOMOTOXICOLOGY: AN EMERGING TOOL IN THE CRIMINAL INVESTIGATION
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Microbiology
- SubjectPharmaceutical Sciences
- SubjectMicrobiology
- BylineArticles whose byline prints “Malcolm Thomas”

